Acid ceramidase confers radioresistance to glioblastoma cells

@article{Doan2017AcidCC,
  title={Acid ceramidase confers radioresistance to glioblastoma cells},
  author={Ninh Doan and Ha Son Nguyen and Mona M. Al-Gizawiy and W M Mueller and Roger Allen Sabbadini and S D Rand and Jennifer Connelly and Christopher R. Chitambar and Kathleen M. Schmainda and Shama Parveen Mirza},
  journal={Oncology Reports},
  year={2017},
  volume={38},
  pages={1932 - 1940}
}
Glioblastoma multiforme (GBM) is the most common primary, intracranial malignancy of the central nervous system. The standard treatment protocol, which involves surgical resection, and concurrent radiation with adjuvant temozolomide (TMZ), still imparts a grim prognosis. Ultimately, all GBMs exhibit recurrence or progression, developing resistance to standard treatment. This study demonstrates that GBMs acquire resistance to radiation via upregulation of acid ceramidase (ASAH1) and sphingosine… 
Glioblastoma chemoresistance: roles of the mitochondrial melatonergic pathway
Treatment-resistance is common in glioblastoma (GBM) and the glioblastoma stem-like cells (GSC) from which they arise. Current treatment options are generally regarded as very poor and this arises
Irradiation of pediatric glioblastoma cells promotes radioresistance and enhances glioma malignancy via genome-wide transcriptome changes
TLDR
It was observed that the changes in multiple biological pathways protected GBM cells against radiation and transformed them to a more malignant form, emphasizing the importance of developing a treatment regimen that consists of a multiple-agent cocktail that acts on multiple implicated pathways to effectively target irradiated pediatric GBM.
Molecular Targeting of Acid Ceramidase in Glioblastoma: A Review of Its Role, Potential Treatment, and Challenges
TLDR
An emerging, novel drug called acid ceramidase, which targets glioblastoma is reviewed, and its role in cancer treatment in general, and more specifically, in the treatment of gliOBlastoma are discussed.
Sphingolipid Metabolism in Glioblastoma and Metastatic Brain Tumors: A Review of Sphingomyelinases and Sphingosine-1-Phosphate
TLDR
The role of sphingolipid metabolism and pharmacological interventions in GBM and metastatic brain tumors with a focus on SMase and S1P is explored, associated with tumor evasion of the immune system and creating a gradient for trafficking of innate and adaptive immune cells.
Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance
TLDR
An effective treatment for radioresistant GBMs may require a cocktail containing multiple agents targeting multiple cancer-inducing pathways in order to have a chance to make a substantial impact on improving the overall GBM survival.
Targeting the Sphingolipid System as a Therapeutic Direction for Glioblastoma
TLDR
The role of sphingolipids in the pathobiology of GBM is discussed, and how targeting sphingoipid metabolism has emerged as a promising approach for the treatment of G BM is discussed.
Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells microenvironment in glioblastoma: Review.
TLDR
A critical analysis of the primary reasons underlying the lack of effectiveness of modern CSC management methods is provided and an emphasis is placed on the role of the blood-brain barrier in the development of treatment resistance.
Targeting Acid Ceramidase to Improve the Radiosensitivity of Rectal Cancer
TLDR
This study demonstrates that expression of AC within colorectal cancer cell lines modulates the cellular response to radiation, and particularly that AC inhibition leads to significantly enhanced radiosensitivity through an elevation in apoptosis, which further solidifies AC as a target for improving radiotherapy treatment of locally advanced rectal cancer.
Sphingolipid/Ceramide Pathways and Autophagy in the Onset and Progression of Melanoma: Novel Therapeutic Targets and Opportunities
TLDR
This review illustrates the role of autophagy in tumor progression and resistance to therapy, focusing on molecular targets for future drugs.
Identification of radiation responsive genes and transcriptome profiling via complete RNA sequencing in a stable radioresistant U87 glioblastoma model
TLDR
Therapeutically, with the global alterations of multiple biological pathways observed in irradiated GBM cells, an effective GBM therapy may require a cocktail carrying multiple agents targeting multiple implicated pathways in order to have a chance at making a substantial impact on improving the overall GBM survival.
...
1
2
3
...

References

SHOWING 1-10 OF 47 REFERENCES
Targeting acid ceramidase sensitises head and neck cancer to cisplatin.
TLDR
AC overexpression is associated with cisplatin sensitivity, suggesting its potential role as a chemotherapeutic target for HNC, and genetic or pharmacological AC inhibition promotes cisPlatin cytotoxicity in HNC cells.
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse.
TLDR
It is demonstrated that ceramide-deacylating enzyme acid ceramidase (AC) was preferentially upregulated in irradiated PCa cells, indicating that AC is a potentially tractable target for adjuvant radiotherapy.
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.
TLDR
The current study on the effects of radiation on prostate cancer cells reveals that radiation programs an unpredicted resistance mechanism by upregulating acid ceramidase (AC), which is, in part, mediated by application of the therapy itself.
Discovery of highly potent acid ceramidase inhibitors with in vitro tumor chemosensitizing activity
TLDR
It is shown that the antineoplastic drug carmofur, which is used in the clinic to treat colorectal cancers, is a potent AC inhibitor and that this property is essential to its anti-proliferative effects.
Recurrent glioblastoma multiforme: a review of natural history and management options.
TLDR
Although recurrent GBM remains a fatal disease, the literature suggests that a subset of patients may benefit from maximal treatment efforts, and further research effort in all aspects of GBM diagnosis and treatment remains essential to improve the overall prognosis of this disease.
Sphingosine-1-Phosphate Regulates Glioblastoma Cell Invasiveness through the Urokinase Plasminogen Activator System and CCN1/Cyr61
TLDR
S1P1 overexpression led to the most dramatic induction of the uPA system and of spheroid invasion, even in the absence of added S1P, and neutralizing antibodies directed against uPA or CCN1 significantly decreased both basal and S 1P-stimulated GBM cell invasiveness.
Potential role of acid ceramidase in conversion of cytostatic to cytotoxic end-point in pancreatic cancer cells
TLDR
The results suggest that acid ceramidase is a viable target in pancreatic cancer and propose that AC inhibition will be effective in concert with other anticancer therapies.
Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages.
TLDR
The anti-S1P mAb substantially reduced tumor progression and in some cases eliminated measurable tumors in murine xenograft and allograft models, validating S1P as a target for therapy.
Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer
TLDR
Findings suggest that S1P inhibition may be a novel therapeutic strategy in patients with treatment-naïve RCC and also in the setting of resistance to VEGFR TKI therapy.
Acid ceramidase inhibition: a novel target for cancer therapy.
TLDR
This review considers the recent work with acid ceramidase inhibitors, in combination with radiation or gene therapy as a sensitizer that enhance cancer therapy.
...
1
2
3
4
5
...